

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 September 2021 (23.09.2021)



(10) International Publication Number
WO 2021/188948 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) C07D 209/12 (2006.01)
A61K 31/4015 (2006.01) C07D 403/00 (2006.01)
A61K 31/404 (2006.01) C07D 403/14 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2021/023233

(22) International Filing Date:

19 March 2021 (19.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/991,763 19 March 2020 (19.03.2020) US
63/123,315 09 December 2020 (09.12.2020) US

(71) Applicant: KYMERA THERAPEUTICS, INC.

[US/US]; 200 Arsenal Yards Blvd., Suite 230, Watertown,
Massachusetts 02472 (US).

(72) Inventors: **JI, Nan**; 5 Stony Brook Road, Arlington, Massachusetts 02476 (US). **WEISS, Matthew M.**; 99 Revere Street, Boston, Massachusetts 02114 (US). **ZHENG, Xiaozhang**; 9 Paddock Lane, Lexington, Massachusetts 02421 (US). **ZHU, Xiao**; 4 Valleywood Circle, Winchester, Massachusetts 01890 (US).

(74) Agent: **REID, Andrea L.C.** et al.; c/o Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MDM2 DEGRADERS AND USES THEREOF

(57) Abstract: The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

WO 2021/188948 A1